Join
Live feed
·
INSIDERFilingvia Quantisnow
Stoke Therapeutics Inc. logo

Director Kaye Edward M. Md converted options into 26,250 shares and sold $402,528 worth of shares (12,567 units at $32.03), increasing direct ownership by 12% to 124,557 units (SEC Form 4) to satisfy withholding obligation

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track STOK (Stoke Therapeutics Inc.) and more on Quantisnow.